Transporters are promising antidiabetic drug targets. Ace Therapeutics provides antidiabetic drug development services targeting transporters. Our services range from identification of diabetes-related transporter targets to preclinical assessment of drug candidates. By combining our expertise in diabetes targets with advanced assays, we aim to help our clients identify promising antidiabetic drugs and accelerate drug discovery targeting transporters.

Overview of Transporters as Antidiabetic Drug Targets

Transporters are often involved in the transport and distribution of endogenous substances and can therefore be targeted for drug development. In diabetes treatment, drugs can be designed to target the transporters that reabsorb glucose in the kidneys to stop the body from conserving glucose. Excess glucose is excreted in the urine, thereby lowering blood glucose levels. For example, the drug glargine, designed to target sodium-glucose cotransporter protein 2 (SGLT2) in the kidneys, blocks the reabsorption of glucose. A range of SGLT2 inhibitors have now been successfully developed for use in type 2 diabetes.

Fig. 1 Mechanisms of action of SGLT2 inhibitors. (Saisho, Y., 2020)

Therefore, transporters can be used as targets for antidiabetic drug development to drive breakthroughs in diabetes drug discovery.

How Can We Support Your Transporter-Targeted Antidiabetic Drug Development Plan?

Ace Therapeutics is committed to providing one-stop services from drug target identification to preclinical discovery of antidiabetic drug candidates for clients worldwide. Our rapid trial initiation and flexible experimental design will help you make faster decisions and reduce your research expenditures.

Diabetes-related transporters identification services

Ace Therapeutics employs bioinformatics technology to identify and validate transporters involved in diabetes mechanisms and to study them in depth. Our diabetes-related transporter identification service is designed to accelerate the drug discovery process, identifying potential targets and guiding the design and optimization of antidiabetic drugs.

Screening and optimization of transporter-targeted antidiabetic drugs

We provide customized screening strategies for antidiabetic drugs based on our clients' needs. We have integrated a number of mainstream in vitro screening technologies, enabling us to offer a comprehensive range of screening services, including:

• Biochemical levels test
• Cellular level test
• Targeting and selectivity screening
• Mechanism of action/signaling pathway/biochemical marker assays

Our efficient and customizable screening systems help clients rapidly identify and optimize antidiabetic drug candidates.

In vitro and in vivo efficacy assessment for transporter-targeted antidiabetic drugs

We evaluate the efficacy of antidiabetic drug candidates through in vitro and in vivo models, with the aim of helping our clients gain a comprehensive understanding of their efficacy and safety.

Preclinical safety assessment for transporter-targeted antidiabetic drugs

Our comprehensive preclinical safety assessment service provides safety data on antidiabetic drugs, reducing side effects and adverse reactions.

We can provide antidiabetic drug development services for the following targets.

Features of Our Transporter-Targeted Antidiabetic Drug Development Services

• Our high-throughput screening technology leads to revolutionary antidiabetic drug development.
• Our reliable in vivo and in vitro diabetes model development services facilitate screening and assessment of antidiabetic drugs.
• We offer flexible and customizable services to meet the diverse needs of clients in the development of transporter-targeted antidiabetic drugs.

Ace Therapeutics' mission is to help our clients develop highly effective, safe and efficacious antidiabetic drugs. To achieve this goal, we offer antidiabetic drug development services targeting transporters. Please feel free to contact us for more details.

References

1. Saisho, Y. SGLT2 inhibitors: the star in the treatment of type 2 diabetes? Diseases. 2020, 8(2): 14.
2. Dahlén, A. D.; et al. Trends in antidiabetic drug discovery: FDA approved drugs, new drugs in clinical trials and global sales. Frontiers in Pharmacology. 2022, 12: 807548.

• Receptor-Targeted Antidiabetic Drug Development
• Enzyme-Targeted Antidiabetic Drug Development

• Mouse Models
• Assay Kits
• Antibodies
• Cell Lines & Lysates
• Proteins & Peptides
• Inhibitors & Activators